whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives

Women are asking whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives.

They're hearing about a stream of lawsuits against these drugs.

Lawyers are targeting Yaz and Yasmin partly due to FDA warnings about the company not adequately disclosing risks in consumer ads.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote